United States· US:0143-9247_032583c8-f4e7-4105-b92e-b5c3f96ca80e
Dexrazoxane
A dexrazoxane product containing dexrazoxane hydrochloride, registered in United States by Hikma Pharmaceuticals USA Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Dexrazoxane is registered in 15 of 19 countries.
Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Dexrazoxane · ATC V03AF02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dexrazoxane costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dexrazoxane · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- FI Finland$8.88
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEXRAZOXANE HYDROCHLORIDE
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Country
- United States (US)
- ATC code
- V03AF02
- ATC class
- Dexrazoxane
- Defined daily dose
- 1.5 g, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1101439247011 VIAL in 1 BOX (0143-9247-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL
- ndc110143-9247-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for dexrazoxane.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dexrazoxane · interactions on record
8 records
- 2 severe
- 6 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- Lactobacillus acidophilusJ07AX04moderate
- DoxorubicinL01DB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Dexrazoxane in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandCardioxaneClinigen Healthcare B.V.
- FinlandCardioxaneNovartis Finland Oy
- FranceCARDIOXANE 500 mg, poudre pour solution pour perfusionCNX THERAPEUTICS IRELAND LIMITED (IRLANDE)
- United KingdomCardioxane 500mg powder for solution for infusion vialsCNX Therapeutics Ltd
- GermanyCardioxaneCnx Therapeutics Ireland Limited
- SpainCARDIOXANE 500 mg POLVO PARA SOLUCION PARA PERFUSIONCnx Therapeutics Ireland Limited
- NetherlandsCardioxane 500 mg poeder voor oplossing voor infusieCNX Therapeutics Ireland Limited
- IrelandSavene 20 mg/ml powder and solvent for concentrate for solution for infusionCNX Therapeutics Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Cyrdanax
- Czechia · Cyrdanax
- Germany · Cardioxane, Cyrdanax
- Spain · Cardioxane
- France · Cardioxane, Cyrdanax
- United Kingdom (Northern Ireland) · Cardioxane
- Hungary · Cyrdanax
- Iceland · Savene
- Italy · Cardioxane
- Liechtenstein · Savene
- Netherlands · Cardioxane
- Norway · Savene
- Poland · Cyrdanax
- Romania · Cyrdanax
- Slovakia · Cyrdanax
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/782c2288-902b-4cce-bc70-37de40743e20 GET /v1/drugs/782c2288-902b-4cce-bc70-37de40743e20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "250",
"substance": "DEXRAZOXANE HYDROCHLORIDE",
"productndc": "0143-9247",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA076068",
"marketing_category": "ANDA"
}See everything about dexrazoxane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.